Main content

    Epilepsy Clinical Trials

    California Pacific Epilepsy Program Opens new window | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at

    Active Trials

    Title: A Randomized, Double-Blind, Placebo Controlled Trial Examining the Safety and Efficacy of Midazolam Intranasal Spray (USL261) for the Treatment of Intermittent Bouts of Increased Seizure Activity in the Epilepsy Monitoring Unit (EMU)
    Description: This study is designed to evaluate the efficacy, safety, and tolerability of USL261 compared with that of intranasal (IN) placebo for the treatment of intermittent bouts of increased seizure activity
    Investigator: David King-Stephens, MD
    Eligibility: Subjects with a clinical diagnosis of partial or generalized epilepsy who have been admitted to the institution's EMU for seizure characterization or pre-surgical evaluation
    Status: Open to enrollment
    Contact: Douglas Raggett, RN, 415-600-3777, Email: about Study EMU

    Title: NeuroPace RNS® System Post-Approval Study in Epilepsy
    Description: This study is to follow patients prospectively over 5 years in the real-world environment to gather data on the long-term safety and effectiveness of the RNS System at qualified Comprehensive Epilepsy Centers by qualified neurologists, epileptologists, and neurosurgeons trained on the RNS System
    Investigator: David King-Stephens, MD
    Eligibility: Subjects 18 years of age or older with frequent, disabling seizures (SPS motor, CPS, or secondarily generalized seizures) and who have failed treatment with a minimum of 2 AEDs, undergone diagnostic testing that has identified no more than 2 epileptogenic foci and who are able to maintain a seizure diary alone or with the assistance of a competent individual
    Status: Coming soon
    Contact: Douglas Raggett, RN, 415-600-3777, Email: about Study NeuroPace PAS

    • updated March 2015